This is an international, randomized, open-label phase 3 trial designed to investigate whether the effective and selective RET inhibitor pralsetinib improves the results of therapy compared to platinum chemotherapy.
Aim of the study
The purpose of this study is to compare the positive or negative effects of pralsetinib with the investigator's choice of standard therapy in patients with non-small cell lung cancer (NSCLC).
Who can take part?
Patients with RET fusion-positive, metastatic non-small cell lung cancer
Procedure
Your study doctor and the study team will inform you in detail about the course of the study.
Compensation
None
Original study name
A randomized, open-label phase III trial of pralsetinib versus standard of care for the initial treatment of RET fusion-positive metastatic non-small cell lung cancer
BASEC number
2020-01921
Financial support from
Roche